Kymera Therapeutics (KYMR) Accumulated Depreciation & Amortization: 2019-2025
Historic Accumulated Depreciation & Amortization for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $22.4 million.
- Kymera Therapeutics' Accumulated Depreciation & Amortization rose 58.70% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.8 million, marking a year-over-year increase of 61.47%. This contributed to the annual value of $16.1 million for FY2024, which is 53.96% up from last year.
- Kymera Therapeutics' Accumulated Depreciation & Amortization amounted to $22.4 million in Q3 2025, which was up 10.64% from $20.2 million recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' Accumulated Depreciation & Amortization registered a high of $22.4 million during Q3 2025, and its lowest value of $2.6 million during Q1 2021.
- In the last 3 years, Kymera Therapeutics' Accumulated Depreciation & Amortization had a median value of $12.5 million in 2024 and averaged $13.7 million.
- Data for Kymera Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY soared of 95.34% (in 2021) over the last 5 years.
- Over the past 5 years, Kymera Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $3.9 million in 2021, then soared by 76.02% to $6.9 million in 2022, then soared by 51.46% to $10.4 million in 2023, then spiked by 53.96% to $16.1 million in 2024, then soared by 58.70% to $22.4 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $22.4 million for Q3 2025, versus $20.2 million for Q2 2025 and $18.1 million for Q1 2025.